Publikationen (64) Publikationen, an denen Forscher/innen teilgenommen haben

2019

  1. 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer

    The Lancet Oncology, Vol. 20, Núm. 10, pp. e566-e581

  2. A new immune-nanoplatform for promoting adaptive antitumor immune response

    Nanomedicine: Nanotechnology, Biology, and Medicine, Vol. 17, pp. 13-25

  3. A quantitative method for the detection of muscle functional active and passive behavior recovery in models of damage-regeneration

    Proceedings of the Institution of Mechanical Engineers, Part L: Journal of Materials: Design and Applications, Vol. 233, Núm. 8, pp. 1594-1603

  4. Adoptive T-cell therapy with CD45RA-depleted donor in the treatment of cytomegalovirus disease in immunocompromised non-transplant patients

    Antiviral Therapy, Vol. 24, Núm. 4, pp. 313-319

  5. Analysis of monocitary subpopulations in relation to cardiovascular risk factors

    Clinica e Investigacion en Arteriosclerosis, Vol. 31, Núm. 4, pp. 152-159

  6. Anisotropic cryostructured collagen scaffolds for efficient delivery of RhBMP-2 and enhanced bone regeneration

    Materials, Vol. 12, Núm. 19

  7. Análisis de subpoblaciones monocitarias en relación con los factores de riesgo cardiovascular

    Clínica e investigación en arteriosclerosis, Vol. 31, Núm. 4, pp. 152-159

  8. Bendamustine as part of conditioning of autologous stem cell transplantation in patients with aggressive lymphoma: a phase 2 study from the GELTAMO group

    British Journal of Haematology, Vol. 184, Núm. 5, pp. 797-807

  9. Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma

    Blood, Vol. 134, Núm. 16, pp. 1337-1345

  10. Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma

    Blood, Vol. 133, Núm. 18, pp. 1953-1963

  11. Circulating microRNAs and their role in multiple myeloma

    Non-coding RNA, Vol. 5, Núm. 2

  12. Clonal hematopoiesis of indeterminate potential–associated mutations and risk of comorbidities in patients with myelodysplastic syndrome

    Cancer, Vol. 125, Núm. 13, pp. 2233-2241

  13. Cost-effective, safe, and personalized cell therapy for critical limb ischemia in type 2 diabetes mellitus

    Frontiers in Immunology, Vol. 10, Núm. JUN

  14. Cytokines in clinical cancer immunotherapy

    British Journal of Cancer, Vol. 120, Núm. 1, pp. 6-15

  15. DNA methylation of enhancer elements in myeloid neoplasms: Think outside the promoters?

    Cancers, Vol. 11, Núm. 10

  16. Daratumumab in combination with urelumab to potentiate anti-myeloma activity in lymphocyte-deficient mice reconstituted with human NK cells

    OncoImmunology, Vol. 8, Núm. 7

  17. Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma

    Blood, Vol. 134, Núm. 5, pp. 421-431

  18. Dual Targeting of Histone Methyltransferase G9a and DNA-Methyltransferase 1 for the Treatment of Experimental Hepatocellular Carcinoma

    Hepatology, Vol. 69, Núm. 2, pp. 587-603

  19. Epigenomic profiling of myelofibrosis reveals widespread DNA methylation changes in enhancer elements and ZFP36L1 as a potential tumor suppressor gene that is epigenetically regulated

    Haematologica, Vol. 104, Núm. 8, pp. 1572-1579

  20. EuroFlow Lymphoid Screening Tube (LST) data base for automated identification of blood lymphocyte subsets

    Journal of Immunological Methods, Vol. 475